Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsX. Cynthia, Helen Piwnica‐Worms|Journal of Clinical Investigation|2012Cited by 222
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Matthew J. Ellis, Eric J. Jaehnig et al.|Nature Communications|2020Cited by 122
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C. Watt, Shom Goel, Paloma Cejas et al.|Nature Cancer|2020Cited by 110
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T. Lei, Matthew J. Ellis, Jieya Shao et al.|Cell Reports|2018Cited by 110